Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases
by Honghui Zhou, Diane R. Mould
15Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins for Plaque Psoriasis – Guselkumab
Zhenling Yao Yaowei Zhu1Chuanpu Hu1Yang Chen1Shu Li2Bruce Randazzo3Zhenhua Xu1Amarnath Sharma1 and Honghui Zhou1
1Janssen Research & Development, LLC, Global Clinical Pharmacology, Spring House, PA, 19477, USA
2Janssen Research & Development, LLC, Statistical and Decision Sciences, Spring House, PA, 19477, USA
3Janssen Research & Development, LLC, Immunology Clinical Development, Spring House, PA, 19477, USA
15.1 Introduction
Psoriasis is a chronic, inflammatory disorder of the skin that affects men and women of all ages and ethnicities. Worldwide, around 2% of individuals are living with psoriatic disease according to the International Federation of Psoriasis Associations (IFPA) and other resources [1]. Plaque psoriasis is the most common form, affecting approximately up to 90% of individuals with psoriatic condition. The disease manifests as raised, well‐demarcated, erythematous, and frequently pruritic and painful plaques with silvery scales [2]. Approximately, one‐fourth of individuals with psoriasis develop moderate‐to‐severe disease with widely disseminated lesions. Symptoms typically present between the ages of 15 and 35, with most of them diagnosed before the age of 40. The majority of sufferers are afflicted with psoriasis for most of their lives.
15.1.1 Pathogenesis of Plaque Psoriasis
Psoriasis is a disorder of immune system dysregulation and the epidermal ...